<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00396877</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5314</org_study_id>
    <secondary_id>2006-000946-38</secondary_id>
    <nct_id>NCT00396877</nct_id>
  </id_info>
  <brief_title>Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation</brief_title>
  <acronym>CLARINET</acronym>
  <official_title>International Randomized Double Blind Study Evaluating the Efficacy and the Safety of Clopidogrel 0.2 mg/kg Once Daily Versus Placebo in Neonates and Infants With Cyanotic Congenital Heart Disease Palliated With Systemic to Pulmonary Artery Shunt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Contemporary management of cyanotic congenital heart disease includes three stages of
      surgery. Incidence of shunt thrombosis and death between the two first stages of palliation
      remains important.

      The primary objective of the study is to evaluate the efficacy of Clopidogrel 0.2 mg/kg/day
      for the reduction of all cause mortality and shunt related morbidity in neonates or infants
      with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt
      (e.g. modified Blalock Taussig Shunt [BTS]).

      The secondary objective was to assess the safety of Clopidogrel in the study population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this event-driven study, participants were to be randomized and treated as soon as
      possible after shunt placement. They were then to be treated and followed until the primary
      endpoint criteria was reached i.e. (shunt thrombosis, the next surgical procedure for
      correction of the congenital heart disease or death) or one year of age or the common
      study-end-date, which ever came first.

      The common study-en-date was defined as the date when it was projected that 172 participants
      would have reached the primary endpoint criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure &lt; 120 Days Considered of Thrombotic Nature)</measure>
    <time_frame>Median follow-up of 5.8 months (up to a maximum of 12 months after randomization)</time_frame>
    <description>The primary endpoint was the first occurence of any of the following events: Death (including heart transplant); Shunt thrombosis requiring intervention; Hospitalization for bi-directional Glenn procedure or any cardiac related intervention prior to 120 days of age following an event or a shunt narrowing considered to be of thrombotic nature by the blinded adjudication committee.
Only the first event was counted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Events</measure>
    <time_frame>From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first</time_frame>
    <description>Bleeding events spanning from signature of the Informed Consent Form up to the last visit were collected as for any Adverse Event.
The 'on-treatment' period was defined as the period from randomization up until 28 days after treatment discontinuation or final follow-up visit, whichever came first, and participants who experienced bleeding events during that period were counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants According to Bleeding Type/Etiology</measure>
    <time_frame>From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first</time_frame>
    <description>For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. Participants who had multiple bleedings could be counted several times.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">906</enrollment>
  <condition>Heart Defects, Congenital</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel 0.2 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel (SR25990)</intervention_name>
    <description>Form: reconstituted solution using Clopidogrel powder
Route: oral or enteric
Frequency: once daily
Dose: daily dose adjusted for weight</description>
    <arm_group_label>Clopidogrel 0.2 mg/kg/day</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Form: reconstituted solution using matching placebo powder
Route: oral or enteric
Frequency: once daily
Dose: daily dose adjusted for weight</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cyanotic congenital heart disease treated by any palliative systemic-to-pulmonary
             artery shunt.

        Exclusion Criteria:

          -  Active bleeding or increase risk of bleeding,

          -  Allergy to 2 or more classes of drug,

          -  Unable to receive drug orally or enterically,

          -  Current clinically significant or persistent thrombocytopenia, neutropenia, severe
             hepatic or renal failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>92 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>International Clinical Development Clinical Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Diegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Shanga√Ø</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Horsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Causeway Bay</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Lysaker</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administraive Office</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Admnistrative Office</name>
      <address>
        <city>Guildford Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2006</study_first_submitted>
  <study_first_submitted_qc>November 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2006</study_first_posted>
  <results_first_submitted>February 15, 2011</results_first_submitted>
  <results_first_submitted_qc>February 15, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2011</results_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cyanotic congenital heart disease</keyword>
  <keyword>shunt palliation</keyword>
  <keyword>thrombosis</keyword>
  <keyword>clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was initially planned with a minimum of 490 participants anticipating that it would continue until a total of 172 participants reaching primary endpoint criteria is achieved. Finally 906 participants were enrolled and randomized between November 2006 and October 2009 in 134 sites in 31 countries. Actual median follow-up was 5.8 months.</recruitment_details>
      <pre_assignment_details>A participant was considered randomized when informed consent had been obtained and there was confirmation of successful allocation of a randomization number through the study treatment allocation system (Interactive Voice Response System).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Reconstituted solution using Clopidogrel matching placebo powder administered once daily with a graduated syringe in the mouth or via a feeding tube.</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel 0.2 mg/kg/Day</title>
          <description>Reconstituted solution using Clopidogrel powder administered once daily with a graduated syringe in the mouth or via a feeding tube.
Route: oral or enteric
Frequency: once daily
Dose: daily dose adjusted for weight</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="439">Randomized</participants>
                <participants group_id="P2" count="467">Randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="436"/>
                <participants group_id="P2" count="464"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="356"/>
                <participants group_id="P2" count="352"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="433">Completed follow-up</participants>
                <participants group_id="P2" count="459">Completed follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent(s)/guardian(s)'s request</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>Clopidogrel 0.2 mg/kg/Day</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="439"/>
            <count group_id="B2" value="467"/>
            <count group_id="B3" value="906"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.0" spread="22.5"/>
                    <measurement group_id="B2" value="36.1" spread="22.3"/>
                    <measurement group_id="B3" value="36.1" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>‚â§ 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 (&lt;) - 92 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="229"/>
                    <measurement group_id="B3" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="0.7"/>
                    <measurement group_id="B2" value="3.4" spread="0.7"/>
                    <measurement group_id="B3" value="3.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeters (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="4.6"/>
                    <measurement group_id="B2" value="51.4" spread="4.4"/>
                    <measurement group_id="B3" value="51.6" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of systemic-to-pulmonary artery shunt palliation</title>
          <description>One participant didn't have a systemic-to-pulmonary artery shunt but underwent stenting of the right ventricular outflow track.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Modified Blalock Taussig Shunt with Norwood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Modified Blalock Taussig Shunt without Norwood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="257"/>
                    <measurement group_id="B3" value="509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sano procedure with Norwood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sano procedure without Norwood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central shunt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stent of ductus arteriosus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not applicable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Shunt on cardiopulmonary bypass</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at shunt palliation</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.0" spread="18.7"/>
                    <measurement group_id="B2" value="16.2" spread="18.6"/>
                    <measurement group_id="B3" value="16.1" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from shunt palliation to randomization</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>‚â§ 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 (&lt;) to 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 (&lt;) to 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure &lt; 120 Days Considered of Thrombotic Nature)</title>
        <description>The primary endpoint was the first occurence of any of the following events: Death (including heart transplant); Shunt thrombosis requiring intervention; Hospitalization for bi-directional Glenn procedure or any cardiac related intervention prior to 120 days of age following an event or a shunt narrowing considered to be of thrombotic nature by the blinded adjudication committee.
Only the first event was counted.</description>
        <time_frame>Median follow-up of 5.8 months (up to a maximum of 12 months after randomization)</time_frame>
        <population>The analysis was performed on the intent-to-treat (ITT) population (i.e. all randomized participants irrespective of whether or not the participant actually received study drug or the participant's compliance with the study protocol). Participants were included in the treatment group to which they were originally allocated.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Clopidogrel 0.2 mg/kg/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure &lt; 120 Days Considered of Thrombotic Nature)</title>
          <description>The primary endpoint was the first occurence of any of the following events: Death (including heart transplant); Shunt thrombosis requiring intervention; Hospitalization for bi-directional Glenn procedure or any cardiac related intervention prior to 120 days of age following an event or a shunt narrowing considered to be of thrombotic nature by the blinded adjudication committee.
Only the first event was counted.</description>
          <population>The analysis was performed on the intent-to-treat (ITT) population (i.e. all randomized participants irrespective of whether or not the participant actually received study drug or the participant's compliance with the study protocol). Participants were included in the treatment group to which they were originally allocated.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="439"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death / Shunt Thrombosis / Cardiac Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Shunt thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Cardiac procedure &lt;120 days of thrombotic nature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to the limited knowledge in this population, 3 interim analyses were performed at approximatively 40%, 60%, 80% and 100% of of the maximum number of 172 required primary efficacy events to evaluate the effect of Clopidogrel on the primary endpoint with the potential to end the trial in case of a clear efficacy advantage for Clopidogrel.
The study was designed with 80% power and an overall type I error rate of 5%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4340</p_value>
            <p_value_desc>The a-priori threshold for statistical significance was &lt; 0.035 reflecting the adjustment for interim analyses. No other adjustment for multiplicity was made.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>A two-sided log-rank test was used.</method_desc>
            <param_type>Relative Risk Reduction (%)</param_type>
            <param_value>11.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.2</ci_lower_limit>
            <ci_upper_limit>33.6</ci_upper_limit>
            <estimate_desc>The Relative Risk Reduction (Clopidogrel versus placebo) and its corresponding 95% confidence interval were estimated using Cox's proportional hazards model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Events</title>
        <description>Bleeding events spanning from signature of the Informed Consent Form up to the last visit were collected as for any Adverse Event.
The 'on-treatment' period was defined as the period from randomization up until 28 days after treatment discontinuation or final follow-up visit, whichever came first, and participants who experienced bleeding events during that period were counted.</description>
        <time_frame>From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first</time_frame>
        <population>The analysis was performed on the exposed population (i.e. all randomized participants who received at least one dose of study drug regardless of the amount of treatment received). Participants were included in the treatment group according to the treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Clopidogrel 0.2 mg/kg/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Events</title>
          <description>Bleeding events spanning from signature of the Informed Consent Form up to the last visit were collected as for any Adverse Event.
The 'on-treatment' period was defined as the period from randomization up until 28 days after treatment discontinuation or final follow-up visit, whichever came first, and participants who experienced bleeding events during that period were counted.</description>
          <population>The analysis was performed on the exposed population (i.e. all randomized participants who received at least one dose of study drug regardless of the amount of treatment received). Participants were included in the treatment group according to the treatment received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="436"/>
                <count group_id="O2" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any bleeding event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Serious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Serious with an outcome of death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Leading to permanent treatment discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants According to Bleeding Type/Etiology</title>
        <description>For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. Participants who had multiple bleedings could be counted several times.</description>
        <time_frame>From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first</time_frame>
        <population>The analysis was performed on the same population as previously (i.e. exposed population).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Clopidogrel 0.2 mg/kg/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants According to Bleeding Type/Etiology</title>
          <description>For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. Participants who had multiple bleedings could be counted several times.</description>
          <population>The analysis was performed on the same population as previously (i.e. exposed population).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="436"/>
                <count group_id="O2" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spontaneous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-traumatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puncture (vascular access site)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AE) regardless of seriousness or relationship to the drug, spanning from signature of the Informed Consent Form up to the last visit were collected.</time_frame>
      <desc>The analysis was performed on the exposed population and included all AE that developed/worsened during the 'on-treatment period' (i.e. from randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever came first).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Clopidogrel 0.2mg/kg/Day</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="234" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CYANOSIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CARDIAC PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CARDIAC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CARDIAC PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>DILATATION VENTRICULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PERICARDIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PULMONARY VALVE STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>LOW CARDIAC OUTPUT SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>NODAL ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>TRICUSPID VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL SEPTAL DEFECT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>COARCTATION OF THE AORTA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>LARYNGOMALACIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERY STENOSIS CONGENITAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PYLORIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>MIDDLE EAR INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>NECROTISING COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ANAL FISSURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>POST-TUSSIVE VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>DUODENAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PNEUMATOSIS INTESTINALIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PUNCTURE SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CATHETER RELATED COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CATHETER THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>FEELING ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VESSEL PUNCTURE SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>MILK ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HYPOGAMMAGLOBULINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>BRONCHIOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PULMONARY SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>NOSOCOMIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>BRONCHITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>BRONCHITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>FUNGAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS ADENOVIRUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS ROTAVIRUS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>LARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PNEUMONIA RESPIRATORY SYNCYTIAL VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ROTAVIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VIRAL RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ABDOMINAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CATHETER SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ENTEROBACTER SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HAEMOPHILUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>IMPETIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>INCISION SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>KLEBSIELLA BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>MEDIASTINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>MENINGITIS PNEUMOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PARAINFLUENZAE VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ESCHERICHIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PNEUMONIA VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PSEUDOMONAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SEPSIS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ADENOVIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CANDIDA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS CALICIVIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>KLEBSIELLA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>MEDIASTINITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>MENINGITIS ASEPTIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PERITONITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PNEUMOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PNEUMONIA INFLUENZAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PNEUMOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VIRAL DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>WOUND ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>WOUND SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>OPERATIVE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE FEVER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SHUNT STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SUTURE RELATED COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>FEEDING TUBE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX TRAUMATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>POST VACCINATION SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PROCEDURAL SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SHUNT BLOOD FLOW EXCESSIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>DEVICE BREAKAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>DRUG TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>GRAFT THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SEROMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SHUNT MALFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SHUNT OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SKULL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SUTURE RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>OXYGEN SATURATION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>BLOOD URINE PRESENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERIAL PRESSURE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ASPIRATION BRONCHIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>OXYGEN SATURATION INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERIAL PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>FEEDING DISORDER OF INFANCY OR EARLY CHILDHOOD</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>WEIGHT GAIN POOR</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>FOOD INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HYPOPROTEINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIC SEIZURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VOCAL CORD PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>POOR SUCKING REFLEX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VOCAL CORD PARESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CLONIC CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>DYSKINESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>EMBOLIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PHRENIC NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE NEONATAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CONVULSIONS LOCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>FEBRILE CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HYDROCEPHALUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ACUTE PRERENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>BLADDER PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VESICOURETERIC REFLUX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PULMONARY HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>DIAPHRAGMATIC PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>STRIDOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>LARYNGEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE AIRWAYS DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PULMONARY VEIN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>TACHYPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>BRONCHOSTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CHYLOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>LARYNGEAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PULMONARY VEIN OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>TRACHEOMALACIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>APNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HAEMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>MEDIASTINAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>MEDIASTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>TRACHEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VOCAL CORD THICKENING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS DIAPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>DERMATITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>RASH PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS EMPHYSEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ANORECTAL OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR EVENT PROPHYLAXIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>URETERONEOCYSTOSTOMY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VENA CAVA THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VASCULAR STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months after trial completion, the Investigator can publish the results. Prior to publication, the sponsor shall review the manuscript and can request changes, provided they do not jeopardize the accuracy and/or the scientific value of the publication. The approval is given in writing by the sponsor, not exceeding 90 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>sanofi-aventis</organization>
      <email>Contact-US@sanofi-aventis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

